Form 4: CVRx CEO Kevin Hykes Receives Significant Equity Grants

CVRx, Inc.'s President and CEO, Kevin Hykes, reported the acquisition of 159,000 restricted stock units and 238,000 stock options, alongside a tax-related sale of 7,763 shares.

Summary

• Kevin Hykes, President & CEO and Director of CVRx, Inc. (CVRX), reported insider transactions.
• Acquired 159,000 shares of common stock in the form of Restricted Stock Units (RSUs) on February 27, 2026, with a grant price of $0. These RSUs vest 25% annually from the grant date.
• Acquired 238,000 stock options on February 27, 2026, with an exercise price of $8.16 and an expiration date of February 26, 2036. These options vest 25% on February 27, 2027, and 1/48th each month thereafter.
• Disposed of 7,763 shares of common stock on March 2, 2026, at a weighted average price of $7.9027 per share, ranging from $7.90 to $8.00. This sale was a "sell-to-cover" transaction mandated by the issuer's award agreement to satisfy tax withholding obligations.
• Following these transactions, Kevin Hykes beneficially owns 284,237 shares of common stock and 238,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant equity grants to the CEO, which align his interests with long-term shareholder value. The associated share sale is a routine tax-related event and does not indicate a negative sentiment.

Positives

• Grant of 159,000 Restricted Stock Units (RSUs) to the President & CEO, aligning management's interests with shareholders.
• Grant of 238,000 stock options with an exercise price of $8.16, providing a long-term incentive for management performance.

Negatives

• Disposal of 7,763 shares of common stock by the President & CEO, although this was a mandated sell-to-cover transaction for tax withholding.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to executive leadership are a standard practice in the medical device and biotechnology sectors, serving to align executive incentives with long-term shareholder value creation. The sell-to-cover transaction for tax obligations is also a common and expected event following equity vesting.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these equity grants, including annual vesting for RSUs and multi-year vesting for options, is consistent with compensation practices seen in comparable medical technology companies such as Medtronic (MDT) or Boston Scientific (BSX), which often use similar long-term incentive plans to retain key talent and drive performance.

Stakeholder Impact

• Shareholders: The grants align the CEO's interests with long-term shareholder value. The tax-related sale is a minor, non-discretionary event.
• Employees: May signal stability and confidence in leadership.

Next Steps

• Vesting of 25% of the 159,000 Restricted Stock Units annually from the grant date.
• Vesting of 25% of the 238,000 stock options on February 27, 2027, followed by monthly vesting of 1/48th of the shares thereafter.

Key Dates

Recommendation

The filing details routine executive compensation in the form of equity grants and a non-discretionary tax-related share sale. While the grants are a positive for long-term incentive alignment, these transactions alone do not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals.

Keywords

CVRx Inc, CVRX, Kevin Hykes, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Equity Grant, CEO Compensation, Sell-to-Cover